PMID- 33247666
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20221207
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 68
IP  - 12[Special]
DP  - 2020 Dec
TI  - Use of Gla-100 in Special Situations.
PG  - 60-66
AB  - Insulin therapy is the cornerstone of diabetes management in people with type 2 
      diabetes mellitus (T2DM). Therefore, its use is recommended even in special 
      populations and situations such as the elderly, pregnant women, obese 
      individuals, people observing religious fasting, and in the presence of 
      comorbidities such as renal insufficiency, and cancer. Since these special 
      situations predispose to complications such as a high risk of hypoglycemia, 
      patients need constant glucose monitoring and insulin dose adjustments, wherever 
      applicable. This review discusses the various considerations that might guide the 
      decision-making process in the special situations alluded to here. It also throws 
      light on how insulin glargine 100 U/mL has emerged as a preferred choice of 
      insulin therapy in most of these situations, on the strength of its inherently 
      low hypoglycemia and weight gain potential, which has found traction even in the 
      recent diabetes guidelines.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - John, Mathew
AU  - John M
AD  - Senior Consultant Endocrinologist, Providence Endocrine and Diabetes Specialty 
      Center, Trivandrum, Kerala.
FAU - Paul, Thomas V
AU  - Paul TV
AD  - Professor, Department of Endocrinology, Diabetes and Metabolism, Christian 
      Medical College, Vellore, Tamil Nadu.
FAU - Joshi, Akhil
AU  - Joshi A
AD  - Senior Consultant Endocrinologist, Sudha Hospital and Medical Research Center, 
      Kota, Rajasthan.
FAU - Kumar, Ravi
AU  - Kumar R
AD  - Consultant Endocrinologist, Endocare Superspeciality Hospital, Nizamabad, 
      Telangana.
FAU - Gupta, P R
AU  - Gupta PR
AD  - Consultant, Apollo Clinic, Howrah, West Bengal.
FAU - Kumar, Shankar
AU  - Kumar S
AD  - Consultant, Department of Internal Medicine, Manipal Hospital, Bangalore, 
      Karnataka.
FAU - Nahata, Kamal
AU  - Nahata K
AD  - Consultant, Dr. Nahata's Clinic, Guwahati, Assam.
FAU - Ravindra, B K
AU  - Ravindra BK
AD  - Medical Affairs, Diabetes and Cardiovascular, Sanofi India Ltd., Mumbai, 
      Maharashtra.
FAU - Mohan, Viswanathan
AU  - Mohan V
AD  - Chairman and Chief Diabetologist, Dr. Mohan's Diabetes Specialities Centre, 
      Chennai, Tamil Nadu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Aged
MH  - Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Pregnancy
EDAT- 2020/11/29 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/11/28 10:08
PHST- 2020/11/28 10:08 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2020 Dec;68(12[Special]):60-66.